171 related articles for article (PubMed ID: 30360810)
1. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model.
Matsumoto K; Le Hoang Doan T; Mai NXD; Nakai K; Komatsu A; Tamanoi F
Enzymes; 2018; 44():103-116. PubMed ID: 30360810
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug.
Mai NXD; Birault A; Matsumoto K; Ta HKT; Intasa-Ard SG; Morrison K; Thang PB; Doan TLH; Tamanoi F
ChemMedChem; 2020 Apr; 15(7):593-599. PubMed ID: 32020745
[TBL] [Abstract][Full Text] [Related]
3. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
4. Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery.
Yu L; Chen Y; Lin H; Du W; Chen H; Shi J
Biomaterials; 2018 Apr; 161():292-305. PubMed ID: 29427925
[TBL] [Abstract][Full Text] [Related]
5. Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models.
Le Hoang Doan T; Mai NXD; Matsumoto K; Tamanoi F
Enzymes; 2018; 44():61-82. PubMed ID: 30360815
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of Mesoporous Silica Nanoparticle with Well-Defined Multicompartment Structure as Efficient Drug Carrier for Cancer Therapy in Vitro and in Vivo.
Wang A; Yang Y; Qi Y; Qi W; Fei J; Ma H; Zhao J; Cui W; Li J
ACS Appl Mater Interfaces; 2016 Apr; 8(14):8900-7. PubMed ID: 26998895
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of "on-demand" drug release using dual tumor marker mediated DNA-capped versatile mesoporous silica nanoparticles.
Wang S; Liu F; Li XL
Chem Commun (Camb); 2017 Aug; 53(62):8755-8758. PubMed ID: 28726871
[TBL] [Abstract][Full Text] [Related]
8. Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape.
Gisbert-Garzarán M; Lozano D; Matsumoto K; Komatsu A; Manzano M; Tamanoi F; Vallet-Regí M
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9656-9666. PubMed ID: 33596035
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
10. Targeted Mesoporous Silica Nanocarriers in Oncology.
Baeza A; Vallet-Regi M
Curr Drug Targets; 2018 Feb; 19(3):213-224. PubMed ID: 27262488
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo.
Ding J; Yao J; Xue J; Li R; Bao B; Jiang L; Zhu JJ; He Z
ACS Appl Mater Interfaces; 2015 Aug; 7(32):18145-55. PubMed ID: 26225796
[TBL] [Abstract][Full Text] [Related]
12. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
13. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
Lu J; Liong M; Li Z; Zink JI; Tamanoi F
Small; 2010 Aug; 6(16):1794-805. PubMed ID: 20623530
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment.
Song C; Wang X; Wang Y; Yu H; Cui Y; Ma T
Curr Drug Metab; 2018; 19(2):131-141. PubMed ID: 28758578
[TBL] [Abstract][Full Text] [Related]
15. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery.
Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M
Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801
[TBL] [Abstract][Full Text] [Related]
16. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics.
Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D
Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Effect of α-Tocopheryl Succinate Delivered by Mitochondria-Targeted Mesoporous Silica Nanoparticles.
Qu Q; Ma X; Zhao Y
ACS Appl Mater Interfaces; 2016 Dec; 8(50):34261-34269. PubMed ID: 27998109
[TBL] [Abstract][Full Text] [Related]
18. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery.
Du X; Li X; Xiong L; Zhang X; Kleitz F; Qiao SZ
Biomaterials; 2016 Jun; 91():90-127. PubMed ID: 27017579
[TBL] [Abstract][Full Text] [Related]
19. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer.
Vu BT; Shahin SA; Croissant J; Fatieiev Y; Matsumoto K; Le-Hoang Doan T; Yik T; Simargi S; Conteras A; Ratliff L; Jimenez CM; Raehm L; Khashab N; Durand JO; Glackin C; Tamanoi F
Sci Rep; 2018 Jun; 8(1):8524. PubMed ID: 29867159
[TBL] [Abstract][Full Text] [Related]
20. Breakable mesoporous silica nanoparticles for targeted drug delivery.
Maggini L; Cabrera I; Ruiz-Carretero A; Prasetyanto EA; Robinet E; De Cola L
Nanoscale; 2016 Apr; 8(13):7240-7. PubMed ID: 26974603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
